Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AIMP2 | Q13155 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.48 |
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334890 | 0.86 | NPC1 (0.47) | NPC1SIGMAR1EGFRERBB2HPGD | |
| SCHEMBL334413 | 0.86 | HPGD (0.45) | NPC1HPGD | |
| SCHEMBL334404 | 0.86 | NPC1 (0.47) | NPC1SIGMAR1EGFRERBB2HPGD | |
| SCHEMBL334943 | 0.84 | NPC1 (0.45) | NPC1SIGMAR1EGFRERBB2HPGD | |
| SCHEMBL20312698 | 0.80 | NPC1 (0.72) | NPC1SIGMAR1EGFRERBB2 | |
| SCHEMBL335221 | 0.77 | HPGD (0.74) | NPC1HPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22307492 | 0.76 | ALPL (0.59) | AIMP2SIGMAR1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL22307899 | 0.76 | ALPL (0.59) | AIMP2SIGMAR1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL22307900 | 0.76 | ALPL (0.59) | AIMP2SIGMAR1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL335234 | 0.76 | NPC1 (0.53) | NPC1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | AIMP2 3333/4885NPC1 209/4885SIGMAR1 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.